Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Next Previous
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary) ; Atorvastatin
  • Indications Cardiovascular disorders; Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms BERSON
  • Sponsors Amgen

    • Most Recent Events

    • 13 Nov 2023 Results assessing the efficacy and safety of ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia on background lipid-lowering therapy presented at the American Heart Association Scientific Sessions 2023
    • 25 Sep 2020 Results (n=1402) of pooled analysis of two trials BANTING and BERSON assessing achievement of ESC/EAS lipid treatment goals with evolocumab in patients with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 01 Sep 2020 Results of pooled analysis of two trials BANTING and BERSON assessing evaluate the achievement of lipid treatment goals with evolocumab vs placebo in T2D presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top